NEW YORK--(BUSINESS WIRE)--Flatiron Health and Via Oncology announced today that Via Pathways for breast, colon, rectal, non-small cell and small-cell lung, mesothelioma, prostate, and multiple myeloma cancers are now available fully embedded in Flatiron Health’s OncoEMR electronic health record (EHR). Via Pathways for additional tumor types will be available throughout 2016. “Using Via Pathways directly in OncoEMR brings real time evidence-based decision support to our clinicians at the point
![]()
↧